FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Novel Drug Approvals Remain Steady in 2026 First Half

[ Price : $8.95]

FDA approval numbers show it approved 23 novel drugs during the first six months of 2026, maintaining a pace that would be consist...

Complete Response on Liver Imaging Agent

[ Price : $8.95]

FDA sends Ascelia Pharma a Complete Response Letter regarding its NDA for Orviglance, a contrast agent for liver imaging.

OIG Backs Manufacturer-Sponsored Patient Tests

[ Price : $8.95]

Two Sheppard attorneys discuss an HHS Inspector General advisory opinion backing a drug companys arrangement with a third-party la...

Former CDC Official Alleges Political Interference In Vaccine Policy

[ Price : $8.95]

During a CBS News interview, former CDC chief medical officer Debra Houry says she left the agency after concluding she could no l...

Insufficient Data on 7 Peptides for Potential Compounding Use: FDA

[ Price : $8.95]

FDA briefing materials show that agency reviewers have found limited evidence supporting the safety and effectiveness of seven pep...

BMC Medical Selling Adulterated, Misbranded CPAPs: FDA

[ Price : $8.95]

FDA warns Chinas BMC Medical that it is marketing adulterated and misbranded ventilators in the U.S. without an approved PMA in pl...

FDA OKs Casgevy for Younger Children

[ Price : $8.95]

FDA approves an expanded age indication for Vertex Pharmaceuticals sickle cell drug Casgevy.

Quality System, Other Violations at 3B Medical

[ Price : $8.95]

FDA warns 3B Medical about multiple violations in its work manufacturing a software device used with ventilator systems imported f...

AseptiKits Marketing Adulterated, Misbranded Devices: FDA

[ Price : $8.95]

FDA warns AseptiKits it is manufacturing and marketing adulterated and misbranded PALA Your Tears medical devices.

FDA Approves BESREMi Pen for Polycythemia Vera

[ Price : $8.95]

FDA approves PharmaEssentias BESREMi injection pen to treat polycythemia vera.